These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 34452444)

  • 21. Impact of Preexisting Hepatitis C Virus Genotype 6 NS3, NS5A, and NS5B Polymorphisms on the
    McPhee F; Ueland J; Vellucci V; Bowden S; Sievert W; Zhou N
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30718256
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Direct-acting antivirals for HCV treatment in older patients: A systematic review and meta-analysis.
    Villani R; Monami M; Di Cosimo F; Fioravanti G; Mannucci E; Vendemiale G; Serviddio G
    J Viral Hepat; 2019 Nov; 26(11):1249-1256. PubMed ID: 31243849
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of pre-treatment hepatitis C virus NS5A resistance associated amino-acid substitutions in genotype 1A infected patients in Scotland.
    Bradley-Stewart A; Goldstein E; MacLean A; Gunson R
    J Clin Virol; 2018 Apr; 101():44-46. PubMed ID: 29414187
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacology Update for the Treatment of Hepatitis C Virus.
    Hopkins L; Dunlap T; Cline H
    Nurs Clin North Am; 2020 Sep; 55(3):347-359. PubMed ID: 32762855
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Hepatitis C virus genotype 4: epidemiology and treatment].
    Castera L; Morice Y; Grando V; Bon C; Dény P; Roulot D
    Gastroenterol Clin Biol; 2003 Jun; 27(6-7):596-604. PubMed ID: 12910223
    [No Abstract]   [Full Text] [Related]  

  • 26. Hepatitis C Virus Diagnosis and the Holy Grail.
    Applegate TL; Fajardo E; Sacks JA
    Infect Dis Clin North Am; 2018 Jun; 32(2):425-445. PubMed ID: 29778264
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection of a sexually transmitted hepatitis C virus protease inhibitor-resistance variant in a human immunodeficiency virus-infected homosexual man.
    Franco S; Tural C; Nevot M; Moltó J; Rockstroh JK; Clotet B; Martinez MA
    Gastroenterology; 2014 Sep; 147(3):599-601.e1. PubMed ID: 24859204
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Importance of HCV genotype 1 subtypes for drug resistance and response to therapy.
    Wyles DL; Gutierrez JA
    J Viral Hepat; 2014 Apr; 21(4):229-40. PubMed ID: 24597691
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Construction and characterization of Genotype-3 hepatitis C virus replicon revealed critical genotype-3-specific polymorphism for drug resistance and viral fitness.
    Guo M; Lu J; Gan T; Xiang X; Xu Y; Xie Q; Zhong J
    Antiviral Res; 2019 Nov; 171():104612. PubMed ID: 31542377
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatitis B and C virus resistance to antiviral therapies--EASL-AASLD-APASL-ALEH-IASL conference.
    Buti M
    IDrugs; 2008 Apr; 11(4):239-41. PubMed ID: 18379952
    [No Abstract]   [Full Text] [Related]  

  • 31. A translational study of resistance emergence using sequential direct-acting antiviral agents for hepatitis C using ultra-deep sequencing.
    Abe H; Hayes CN; Hiraga N; Imamura M; Tsuge M; Miki D; Takahashi S; Ochi H; Chayama K
    Am J Gastroenterol; 2013 Sep; 108(9):1464-72. PubMed ID: 23896953
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Profile of alisporivir and its potential in the treatment of hepatitis C.
    Gallay PA; Lin K
    Drug Des Devel Ther; 2013; 7():105-15. PubMed ID: 23440335
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New hepatitis C therapies: the toolbox, strategies, and challenges.
    Pawlotsky JM
    Gastroenterology; 2014 May; 146(5):1176-92. PubMed ID: 24631495
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatitis C virus infection in Taiwan: Past, present, and future.
    Kao JH
    J Formos Med Assoc; 2016 Feb; 115(2):65-6. PubMed ID: 26228687
    [No Abstract]   [Full Text] [Related]  

  • 35. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b.
    Suzuki F; Sezaki H; Akuta N; Suzuki Y; Seko Y; Kawamura Y; Hosaka T; Kobayashi M; Saito S; Arase Y; Ikeda K; Kobayashi M; Mineta R; Watahiki S; Miyakawa Y; Kumada H
    J Clin Virol; 2012 Aug; 54(4):352-4. PubMed ID: 22658798
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Forthcoming challenges in the management of direct-acting antiviral agents (DAAs) for hepatitis C.
    Bruno R; Cima S; Maiocchi L; Sacchi P
    Dig Liver Dis; 2011 May; 43(5):337-44. PubMed ID: 20980211
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Development status of DAA against hepatitis C].
    Kato N; Nakagawa R; Goto K; Muroyama R; Matsubara Y
    Nihon Rinsho; 2015 Dec; 73 Suppl 9():262-8. PubMed ID: 26845942
    [No Abstract]   [Full Text] [Related]  

  • 38. A Prospective Italian Study on Baseline NS3 and NS5A Resistance to Direct-Acting Antivirals in a Real-World Setting of HIV-1/HCV Coinfected Patients and Association with Treatment Outcome.
    Bagaglio S; Hasson H; Peano L; Vercesi R; Messina E; Galli A; Foppa CU; Morsica G
    Viruses; 2020 Feb; 12(3):. PubMed ID: 32121164
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New Therapies for Hepatitis C Virus.
    Polenakovik H
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2015; 36(2):119-32. PubMed ID: 27442378
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use.
    Bagaglio S; Uberti-Foppa C; Morsica G
    Drugs; 2017 Jul; 77(10):1043-1055. PubMed ID: 28497432
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.